8-K filing — Tectonic Therapeutic, Inc. (TECX)

Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93

Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.

Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate

Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses of $(1.07) per share

Tectonic Therapeutic Completes Enrollment For The APEX Trial, A 24-Week Phase 2 Clinical Trial Evaluating The Safety And Efficacy Of TX45 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction; APEX Phase 2 Trial Enrolled 191 Patients Across 14 Countries, With ~72% Of Patients In The Enriched Population Of CpcPH With A Pulmonary Vascular Resistance >3 WU At Baseline